Novartishas acquired an investigational cytomegalovirus (CMV) vaccine programme from the US-based vaccine developer AlphaVax for $20 million.
The acquisition of the CMV programme adds to Novartis's early-stage vaccine pipeline that focuses on meningococcal infections and other hospital...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?